Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | MDH1 | P40925 | 1/20 | 0.36 |
| ▸ | MDH2 | P40926 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765281 | 0.84 | EPHX2 (0.33) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL27845478 | 0.83 | LMNA (0.61) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL21765283 | 0.81 | KDM4C (0.33) | EPHX2KDM4C | |
| SCHEMBL15055320 | 0.76 | ALDH1A1 (0.79) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL19638852 | 0.76 | ALDH1A1 (0.79) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL21752967 | 0.76 | LMNA (0.52) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL16216731 | 0.76 | LMNA (0.52) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL21752924 | 0.75 | MEN1 (0.44) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL21752960 | 0.75 | MEN1 (0.50) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL16628067 | 0.74 | MDH1 (0.45) | MEN1KMT2ALMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-3841091-A1 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERATIVE ACTIVITY | Xeniopro GmbH (DE) | 2021-06-30 | — | — | EP | disclosed |
| CN-112930337-A | Antiproliferative phenoxy (hetero) aryl ethers | 赛尼欧普罗有限责任公司 | 2021-06-08 | — | — | CN | disclosed |
| WO-2020039094-A1 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERATIVE ACTIVITY | Xeniopro GmbH (DE) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | AHR, MUSK, TYR | MEN1 4794/4885KMT2A 762/4885LMNA 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.